SC 13G/A

Names of Reporting Persons

Genexine, Inc..

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Republic of Korea

SC 13G/A 1 d149648dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Amendment No. 1 to

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURUSANT

TO § 240.13d-2

I-MAB

(Name of Issuer)

Ordinary Shares, par value $0.0001⁽¹⁾

(Title of Class of Securities)

44975P103

(CUSIP Number)⁽²⁾

May 19, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

¹	Some of the holdings reported herein are in the form of American Depositary Shares (“ADS”), which may be exchanged for ordinary shares of the Issuer, par value $0.0001 (“Ordinary Shares”) at a 10:23 ratio.

²	The CUSIP Number listed throughout this filing is the CUSIP assigned to the ADS of the Issuer.

CUSIP No. 44975P 103

⁽³⁾	See Item 4 of this Statement for more information.

⁽⁴⁾	This percentage is calculated based on 170,745,354 Ordinary Shares outstanding as of April 30, 2021 as provided by the Issuer.

Item 1(a) Name of issuer: I-Mab

Item 1(b) Address of issuer’s principal executive offices:

Suite 802, West Tower, OmniVision 88 Shangke Road, Pudong District Shanghai, 201210 People’s Republic of China

2(a) Name of person filing:

Genexine, Inc.

2(b) Address or principal business office or, if none, residence:

Genexine, Inc.

B-4 700, Daewangpangyo-ro, Bundang-gu

Seongnam-si, Gyeonggi-do

Republic of Korea

2(c) Citizenship:

Republic of Korea

2(d) Title of class of securities:

Ordinary shares, par value of $0.0001 per share

2(e) CUSIP No.:

44975P 103

There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 44975P103 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “IMAB.” Each 10 ADSs represents 23 Ordinary Shares.

Item 3.

Type of Person.

(i)

Item 4.

Ownership

The information set forth in rows 5 through 11 of the cover page hereto for each of the Reporting Persons is incorporated herein by reference.

Item 5.

Ownership of 5 Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person.

N/A

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

N/A

Item 8.

Identification and Classification of Members of the Group.

N/A

Item 9.

Notice of Dissolution of Group.

N/A

Item 10.

Certifications.

By signing below I certify that, to the best of knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: June 18, 2021	By:	GENEXINE, INC.

		By	\s\ Sung June Hong
		Name	Sung June Hong
		Its CFO

SEC Form SC 13G/A filed by I-MAB (Amendment)